Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)
China · Delayed Price · Currency is CNY 27.31
-0.63 (-2.25%)
Sep 11, 2026, 3:00 PM CST
SHA:688319 Revenue
Chengdu Olymvax Biopharmaceuticals had revenue of 203.52M CNY in the quarter ending June 30, 2026, a decrease of -6.80%. This brings the company's revenue in the last twelve months to 759.63M, up 13.64% year-over-year. In the year 2025, Chengdu Olymvax Biopharmaceuticals had annual revenue of 704.16M with 19.58% growth.
Revenue (ttm)
759.63M
Revenue Growth
+13.64%
P/S Ratio
14.59
Revenue / Employee
1.74M
Employees
436
Market Cap
11.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 704.16M | 115.30M | 19.58% |
| Dec 31, 2024 | 588.86M | 92.74M | 18.69% |
| Dec 31, 2023 | 496.12M | -51.36M | -9.38% |
| Dec 31, 2022 | 547.48M | 60.33M | 12.38% |
| Dec 31, 2021 | 487.15M | 167.04M | 52.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Nanjing Vazyme Biotech | 1.47B |
| Shanghai Medicilon | 1.38B |
| Hualan Biological Vaccine | 1.19B |
| GemPharmatech | 878.13M |
| Mabwell (Shanghai) Bioscience | 873.99M |